| Anticancer Fund

How to optimize cancer research for the benefit of the patient?

Tue, 03/30/2021 - 12:00

A publication by scientists of the Anticancer Fund

A prospective phase II, randomised multi-center trial of a biomodulatory treatment with metronomic low-dose treosulfan, pioglitazone and clarithromycin versus nivolumab in patients with lung cancer, after platin failure (ModuLung).

Daniel Heudoble, Christian Schulz, Jürgen R. Fischer, Peter Staib, Thomas Wehler, Thomas Südhoff, Thomas Schichtl, Jochen Wilke, Joachim Hahn, Florian Lüke, Martin Vogelhuber, Sebastian Klobuch, Tobias Pukrop, Wolfgang Herr, Swantje Held, Kristine Beckers, Gauthier Bouche, Albrecht Reichle. A Randomized Phase II Trial Comparing the Efficacy and Safety of Pioglitazone, Clarithromycin and Metronomic Low-Dose Chemotherapy with Single-Agent Nivolumab Therapy in Patients with Advanced Non-small Cell Lung Cancer Treated in Second or Further Line (ModuLung). Front. Pharmacol., 16 March 2021,doi.org/10.3389/fphar.2021.599598

Tue, 03/16/2021 - 12:00

An Open Access Database of Licensed Cancer Drugs

Pan Pantziarka, Rica Capistrano I, Arno De Potter, Liese Vandeborne and Gauthier Bouche. An Open Access Database of Licensed Cancer Drugs. Frontiers in Pharmacology, 2021, doi: 10.3389/fphar.2021.627574

Thu, 03/11/2021 - 12:00

The European Union and personalised cancer medicine

John A. Hickman, Ian F. Tannock, Lydie Meheus, Lisa Hutchinson. The European Union and personalised cancer medicine. European Journal of Cancer, 150 (2021) 95e98, doi.org/10.1016/j.ejca.2021.03.013

Mon, 03/08/2021 - 12:00

From lab to life: transforming childhood, adolescent and rare cancer care

Mon, 03/01/2021 - 12:00

Discover our Annual Report 2020

Mon, 02/15/2021 - 12:00

World Cancer Day - Because every patient deserves optimal treatment

Thu, 02/04/2021 - 12:00

The Anticancer Fund supports EORTC trial in oligometastatic rare cancers with Rising Tide Foundation

Tue, 02/02/2021 - 12:00